FOXA1 condensates unpack heterochromatin and activate tumor suppressor genes. Mutations in DNA-binding domain of FOXA1 abrogate its tumor-suppressive function driven by heterochromatin targeting and condensate formation in breast and prostate cancers. Here, FOXA1 is linked to prostate cancer.